Pharma-collaborations to secure success of Danish biotech company
It is collaborations with the big pharmaceutical companies, rather than investors, that are to secure operations in a Danish biotech company which makes it living updating existing medicine.
af KRESTEN MORTEN MUNKSGAARD
It is not investors but close collaborations with the established pharmaceutical industry that are going to ensure the continued operation of the Danish biotech company Ascendis Pharma, the company chairman tells Danish business daily Børsen, after Ascendis emerged from 2011 with a DKK 90.1 million deficit. The shareholders equity was DKK 125.7 million at the end of 2011 against 174.3 million at the end of 2010.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
